Comparative Pharmacology
Head-to-head clinical analysis: LYUMJEV versus SYNJARDY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYUMJEV versus SYNJARDY.
LYUMJEV vs SYNJARDY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYUMJEV (insulin lispro-aabc) is a rapid-acting insulin analog that binds to the insulin receptor (IR), activating the IR tyrosine kinase cascade. This leads to increased glucose uptake in peripheral tissues (primarily skeletal muscle and adipose tissue), inhibition of hepatic gluconeogenesis, and promotion of glycogen synthesis. The aabc amino acid substitution (insulin lispro with proline at B28 replaced by lysine and lysine at B29 replaced by proline, plus an additional modification) results in faster dissociation from the insulin receptor and accelerated absorption from subcutaneous tissue compared to regular human insulin.
SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Empagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin inhibits DPP-4, increasing incretin hormone levels (GLP-1, GIP), which stimulate insulin release and decrease glucagon secretion.
Subcutaneous injection at mealtime (within 15 minutes before or immediately after meal). Doses individualized; typical range 0.2-1.0 units/kg/day.
Initial: 5 mg empagliflozin/1000 mg metformin hydrochloride extended-release orally twice daily with meals. Titrate based on glycemic control, up to maximum of 25 mg/2000 mg per day (given as 12.5 mg/1000 mg twice daily).
None Documented
None Documented
Terminal elimination half-life of LYUMJEV (insulin lispro) is approximately 13.7 minutes (0.23 hours) in healthy subjects, reflecting rapid clearance from the bloodstream.
Empagliflozin: terminal half-life ~12.4 hours (supports once-daily dosing). Metformin: terminal half-life ~6.2 hours in plasma, but prolonged to ~17.6 hours in whole blood due to RBC binding; clinical effect duration aligns with daily dosing.
Primarily renal; approximately 90% of absorbed dose is excreted via urine as metabolites and unchanged drug, with the remainder eliminated in feces (<10%).
Renal: ~95% of empagliflozin as unchanged drug; ~20% of metformin as unchanged drug via glomerular filtration and tubular secretion. Fecal: <1% for empagliflozin; ~30% of metformin as unchanged drug. Biliary: negligible.
Category C
Category C
Antidiabetic
Antidiabetic